Urogen Pharma Ltd. (URGN) SEC Filings — 2025
11 SEC filings for Urogen Pharma Ltd. (URGN) in 2025.
Filings
- UroGen Pharma's Losses Widen Amid Soaring Expenses, Cash Drains — 10-Q · Nov 6, 2025
- UroGen Pharma Ltd. Announces Executive and Board Changes — 8-K · Aug 27, 2025
- UroGen Pharma Corrects Q2 2024 EPS, Adjusts Prepaid Obligations — 10-Q · Aug 7, 2025
- UroGen Pharma Details Executive Equity Awards Ahead of Shareholder Vote — DEF 14A · Jul 15, 2025
- UroGen Pharma Ltd. Reports Board and Executive Changes — 8-K · Jul 3, 2025
- Deciphera to Acquire UroGen Pharma for $750M — 8-K · Jun 13, 2025
- UroGen Pharma Q1 2025: $100M Assets, $8.8M Net Loss — 10-Q · May 12, 2025
- UroGen Pharma Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025
- UroGen Pharma Ltd. Files 2024 10-K — 10-K · Mar 10, 2025
- UroGen Pharma Ltd. Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 20, 2025
- UroGen Pharma Files 8-K — 8-K · Jan 14, 2025